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In this study, the potential of the amino-terminal sequence from the F1 polypeptide responsible for the fusion of measles
virus (MV) with cell membranes as a carrier system for a CTL epitope from the MV nucleoprotein was examined. The
addition of the fusion sequence (FP) at either the amino or the carboxyl terminus of the CTL epitope peptide rendered it
immunogenic after intraperitoneal immunization in mice. The CTLs induced were able to lyse target cells pulsed with the
peptide or persistently infected with MV. After intranasal administration of a FP–CTL chimera with or without cholera toxin
B subunit (CTB) as an adjuvant, CTL responses to the peptide pulsed and to MV-infected target cells were detected.
Responses in groups of mice where CTB was used as an adjuvant were stronger. However, intranasal administration of
the CTL epitope did not induce a protective response against intracranial challenge with a neuroadapted strain of MV.
These findings highlight the potential of fusion sequences as a carrier system for CTL epitopes and the potential of the
intranasal route for administration of synthetic peptides representing MV sequences. q 1996 Academic Press, Inc.
Measles virus (MV) is a cause of an acute infection in peptide immunogens with the potential to induce CTL
responses requires that the peptides have the ability toearly childhood and despite the existence of a successful
vaccine, the virus still remains a major cause of infant insert into the cell membrane of antigen-presenting cells
and facilitate processing via the class I pathway. Themortality in developing countries. Thus, there is an urgent
need for the development of new vaccines, particularly penetration of MV into the cells requires the fusion of
the viral envelope with the cell membrane. For this eventthose which can successfully induce immunity to MV
to occur the F surface glycoprotein of the virus has toeven in the presence of maternal antibodies.
be cleaved (by a host protease) to yield the disulfide-An acute MV infection is normally followed by lifelong
linked active form of the protein consisting of the F1 andimmunity in which the presence of neutralizing antibod-
the F2 polypeptides (7, 8). The amino terminus of the F1ies against the virus surface glycoproteins H and F are
polypeptide is very hydrophobic and it has been pro-critical (1). However, patients with depressed T-cell re-
posed to play an important role in the induction of fusionsponses suffer from severe complications (2) and the
between the virus envelope and the lipid bilayer of cellimportance of cytotoxic T-lymphocytes in controlling MV
membranes (7). In the present study, the potential of theinfection is still unclear. Several studies have suggested
amino-terminal sequence from the F1 polypeptide as athat CD8/ T-cells may be important in recovery from
carrier system for a CTL epitope from the MV nucleopro-measles infection (3, 4) and the possibility exists that
tein (NP) was examined after parenteral or intranasalthey may function as memory cells in maintaining lifelong
administration.immunity against measles (5).
Residues 113–125 (FAGVVLAGAAL) represent the firstCD8/ T-lymphocytes kill virally infected cells when
12 amino acids from the amino terminus of the F1 poly-their T-cell receptors recognize endogenously synthe-
peptide of the fusion protein of MV, which is very hy-sized viral peptides associated with major histocompati-
drophobic and has a high degree of homology with thebility complex class I glycoproteins (6). Replicating vec-
amino terminus of the F1 polypeptide of the rest of thetors have generally been used for the induction of CTL
paramyxoviruses (9). Peptides representing residues 51–responses but their use as vaccines in humans is prob-
59 (NP6) (LDRLVRLIG) and 81–88 (NP9) (VESPGQLI) oflematic and thus immunization with synthetic peptides
the NP of MV, previously identified as CTL epitopes inmay be more appropriate. The development of synthetic
the H-2k strain of mice (11), were synthesized by solid-
phase synthesis using Fmoc chemistry. In addition pep-
tides were produced in which the 81–88 CTL epitope1 To whom correspondence and reprint requests should be ad-
dressed. Fax: /44 171 6374314. E-mail: C.Partidos@lshtm.ac.uk. was colinearly synthesized at either the amino (NP9-F)
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FIG. 1. CTL induced after intraperitoneal immunization of CBA mice with NP9 (j), F-NP9 (l), and NP9-F (m) peptides emulsified in IFA. After in
vitro restimulation of spenocytes with NP9 peptide, effector cells were cocultured (a) with L929 target cells pulsed ( ) or not pulsed (- - -) with
NP9 peptide or (b) with persistently infected MV NS20Y/MS cells (12, 13) ( ) or noninfected NS20Y cells (- - -) at the indicated E:T ratios.
Spontaneous release was between 10 and 25% of total release by detergent in all assays. All assays were performed in triplicate and SD of triplicate
wells was consistently less than 10% of the mean.
or carboxyl terminus (F-NP9) of the fusogenic peptide than in the group of mice in which the peptide was ad-
ministered in saline.113–125 (F).
The immunogenicity of NP9, F-NP9, and NP9-F pep- As the F-NP9 peptide can induce MV-specific CTL re-
sponses, its capacity to protect against MV-inducedtides was tested after intraperitoneal immunization of
groups of three CBA (H-2k) mice (6–8 weeks old) with mouse encephalomyelitis (14) was assessed after intra-
nasal administration. Peptide-immunized mice were100 mg of each peptide emulsified in IFA. Two weeks
after priming, effector splenocytes were restimulated in tested for the presence of CTLs and as shown in Table
1, mice immunized with F-NP9 peptide and CTB as anvitro with NP9 peptide and tested for CTL activity as
previously described (11). Effector cells from mice immu- adjuvant mounted a good CTL response. Following intra-
cranial challenge with neuroadapted MV the peptide-nized with NP9 peptide did not show significant cytolytic
activity against L929 target cells pulsed with the homolo- immunized group survived longer than mice in the control
group (Fig. 3). By Day 30, 40% of the peptide-immunizedgous peptide (Fig. 1a). However, effector cells from mice
immune to F-NP9 or NP9-F peptides were able to kill mice but only 25% of the control mice had survived. These
differences were not statistically significant using theL929 target cells pulsed with the NP9 peptide, but not
unpulsed cells (Fig. 1a). Furthermore, these effector cells Fisher–Irwin exact test.
To generate virus-specific CTLs in vivo, priming is gen-could also lyse persistently MV-infected NS20Y/MS tar-
get cells but not noninfected NS20Y target cells (Fig. 1b). erally required. This can be achieved by means of prim-
ing with antigen incorporated into immune stimulatingGiven that the linkage of the NP9 peptide to the fuso-
genic peptide (F) renders it immunogenic after parenteral complexes (15), liposomes (16), Ty-virus-like particles
(17), or by conjugation to synthetic lipopeptides (18).immunization, its ability to induce MV-specific CTL re-
sponses after intranasal administration was also evalu- However, although successful induction of CD8/ cells
has been demonstrated, the use of these approachesated. Groups of three CBA mice (6–8 weeks old) were
immunized intranasally with 50 mg/dose of the F-NP9 might be problematic for human use due to the nature
of the derivitized materials used. In this report we havepeptide in 30 ml phosphate-buffered saline on 3 consecu-
tive days with or without cholera toxin B subunit (CTB, demonstrated that a synthetic peptide representing a
CTL epitope can induce CTL responses in vivo whenSigma) as an adjuvant (10 mg/dose). After 3 weeks, mice
received a booster intranasal administration of 50 mg/ linked to a fusogenic peptide sequence. Moreover, it was
shown that the orientation of the fusogenic peptide indose of peptide with or without CTB (10 mg/dose). Two
weeks later, effector splenocytes were restimulated in relation to the CTL epitope did not have an effect on the
immunogenicity of these FP–CTL chimeras. The mecha-vitro with NP9 peptide and tested for their CTL activity.
As shown in Figs. 2a and 2b, splenocytes from both nisms by which these FP–CTL chimeras induce CTL
responses are not yet known. However, the structuralgroups of mice effectively lysed L929 and NS20Y target
cells pulsed with NP9 peptide but not unpulsed cells. characteristics of the fusion sequence suggest that it
has a highly hydrophobic helical structure (8) which fusesMoreover, these cells could lyse NS20Y/MS cells persis-
tently infected with MV (Fig. 2c). CTL responses observed with the cell membranes of antigen-presenting cells
(APCs) and facilitates the translocation through the endo-in the group of mice in which commercial CTB was used
as an adjuvant were much higher even at a 3:1 E:T ratio plasmic reticulum. In this way the CTL epitope is intro-
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FIG. 2. CTL activity induced after intranasally priming CBA mice with F-NP9 chimeric peptide with CTB (m) or in saline (j). After in vitro
restimulation of splenocytes with NP9 peptide, effector cells were cocultured with (a) L929, (b) NS20Y target cells pulsed with the NP9 peptide at
the indicated E:T ratios, or (c) the persistently infected MV NS20Y/MS cell line. Data are presented as percentage net specific lysis by subtracting
the background lysis. Background lysis using unpulsed L929 cells ranged from 23.07% to 2.58% at 100:1 and 3:1 E:T ratios, respectively, and for
unpulsed or noninfected NS20Y cells from 10.16% to 1.16% at 100:1 and 3:1 E:T ratios, respectively.
duced into the class I presentation pathway. It has been the fusion peptide sequence can inhibit both cell fusion
and virus penetration (19, 20). There is also evidencesuggested that the amino terminus of the F1 polypeptide
of MV plays an important role in the induction of fusion for the interaction of the fusion peptide with target lipid
between the virus envelope and the lipid bilayer of cell
membranes (7, 8). Evidence in support of this notion in-
cludes the finding that synthetic peptides able to mimic
TABLE 1
CTL Activity Expressed as Percentage Specific Lysis Induced after
Priming of 3-Week-Old CBA Mice with F-NP9 Chimeric Peptide
Using CTB as an Adjuvant
Target cells
E/T ratio L929 L929 / NP9 L929 / NP6
100/1 11 54.2 8.5
50/1 12.3 38.4 12.15
25/1 5.5 26.8 7.4
12/1 4.5 15.2 4.2
6/1 0.7 9.4 0 FIG. 3. CBA mice (3 weeks old) were immunized intranasally with
PBS (j) (8 mice) or 50 mg/dose F-NP9 chimeric peptide with 10 mg/3/1 0 5.4 0
dose CTB (m) (10 mice). Mice were initially immunized three times on
consecutive days and 2 weeks later were boosted with 50 mg/dose ofNote. After in vitro restimulation of splenocytes with NP9 peptide,
CTL responses were measured (see ref. 11) by coculturing effector peptide with 10 mg/dose CTB and challenged by intracerebral injection
of 104 PFU in a 25-ml volume of a neuroadapted strain of MV (CAM/cells with L929 target cells pulsed with NP9, the unrelated NP6 peptide,
or nonpulsed target cells, at the indicated E/T ratio. RBH).
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conducting the protection studies. We also thank Dr. U. Liebert (Institutebilayers obtained by labeling with photoactive lipid
fu¨r Virologie und Immunobiologie, Wurzburg, Germany) for kindly pro-probes (21). Alternatively, the ability of the FP–CTL chi-
viding the rodent-neuroadapted strain of MV (CAM/RBH) and Professor
mera to induce CTL responses might be the result of a B. Rager-Zisman (Dept of Microbiology & Immunology, Ben Gurion,
prolonged accessibility of the CTL epitope due to either University of the Negev, Israel) who kindly provided the NS20Y and
its increased hydrophobicity or its resistance to proteo- NS20Y/MS cell lines. This is publication 1113 from the Department of
Clinical Sciences.lytic degradation (22).
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